CL2018002834A1 - Protozoo modificado que expresa al menos dos proteínas variables de superficie (vsp), vacuna que lo comprende, procedimientos, usos y métodos (divisional solicitud 201101309) - Google Patents

Protozoo modificado que expresa al menos dos proteínas variables de superficie (vsp), vacuna que lo comprende, procedimientos, usos y métodos (divisional solicitud 201101309)

Info

Publication number
CL2018002834A1
CL2018002834A1 CL2018002834A CL2018002834A CL2018002834A1 CL 2018002834 A1 CL2018002834 A1 CL 2018002834A1 CL 2018002834 A CL2018002834 A CL 2018002834A CL 2018002834 A CL2018002834 A CL 2018002834A CL 2018002834 A1 CL2018002834 A1 CL 2018002834A1
Authority
CL
Chile
Prior art keywords
surface proteins
vsp
variable surface
vaccine
procedures
Prior art date
Application number
CL2018002834A
Other languages
English (en)
Inventor
Hugo Daniel Lujan
Original Assignee
Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet
Univ Catolica De Cordoba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet, Univ Catolica De Cordoba filed Critical Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet
Publication of CL2018002834A1 publication Critical patent/CL2018002834A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/68—Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/10—Protozoa; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PROTOZOOS PARÁSITOS MODIFICADOS QUE COMPRENDEN LA EXPRESIÓN SIMULTÁNEA EN SU SUPERFICIE DE AL MENOS DOS PROTEÍNAS VARIABLES DE SUPERFICIE (VSP). LOS PROTOZOOS MODIFICADOS PUEDEN TAMBIÉN EXPRESAR EN FORMA SIMULTÁNEA EL REPERTORIO COMPLETO DE PROTEÍNAS VARIABLES DE SUPERFICIE. LOS PROTOZOOS MUESTRAN UNA EXPRESIÓN REDUCIDA DE LAS ENZIMAS DICER, ARN POLIMERASA RNA DEPENDIENTE (RDRP) O AMBAS, EN DONDE EL GEN RDRP Y/O EL GEN DICER HA SIDO SILENCIADO. EL PROTOZOO PUEDE SER CUALQUIER PROTOZOO QUE PRESENTE UN MECANISMO DE VARIACIÓN ANTIGÉNICA.
CL2018002834A 2008-12-02 2018-10-04 Protozoo modificado que expresa al menos dos proteínas variables de superficie (vsp), vacuna que lo comprende, procedimientos, usos y métodos (divisional solicitud 201101309) CL2018002834A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11905808P 2008-12-02 2008-12-02

Publications (1)

Publication Number Publication Date
CL2018002834A1 true CL2018002834A1 (es) 2019-04-05

Family

ID=42233679

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2011001309A CL2011001309A1 (es) 2008-12-02 2011-06-02 Protozoo parásito modificado que posee una expresión simultanea de al menos dos proteínas variables de superficie (vsp); vacuna que lo comprende; y uso.
CL2018002834A CL2018002834A1 (es) 2008-12-02 2018-10-04 Protozoo modificado que expresa al menos dos proteínas variables de superficie (vsp), vacuna que lo comprende, procedimientos, usos y métodos (divisional solicitud 201101309)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2011001309A CL2011001309A1 (es) 2008-12-02 2011-06-02 Protozoo parásito modificado que posee una expresión simultanea de al menos dos proteínas variables de superficie (vsp); vacuna que lo comprende; y uso.

Country Status (18)

Country Link
US (1) US9463229B2 (es)
EP (1) EP2364156B1 (es)
JP (3) JP2012510286A (es)
CN (1) CN102281884B (es)
AR (1) AR074458A1 (es)
AU (1) AU2009323734B2 (es)
BR (1) BRPI0917075B1 (es)
CA (1) CA2745470C (es)
CL (2) CL2011001309A1 (es)
CO (1) CO6390115A2 (es)
CR (1) CR20110377A (es)
EC (1) ECSP11011171A (es)
ES (1) ES2667773T3 (es)
MX (2) MX351579B (es)
NZ (2) NZ604943A (es)
PE (2) PE20150889A1 (es)
PT (1) PT2364156T (es)
WO (1) WO2010064204A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9457096B2 (en) 2012-07-06 2016-10-04 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet) Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512288A (en) * 1992-12-04 1996-04-30 University Technologies International, Inc. Giardia vaccine
US5585250A (en) * 1993-08-20 1996-12-17 The United States Of America As Represented By The Department Of Health & Human Services Dampening of an immunodominant epitope of an antigen for use in plant, animal and human compositions and immunotherapies
US6171820B1 (en) * 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
JP2000083677A (ja) * 1998-09-17 2000-03-28 Bayer Ltd ダニワクチン
GB0000474D0 (en) * 2000-01-10 2000-03-01 Inal Jameel M Receptor

Also Published As

Publication number Publication date
NZ604943A (en) 2014-08-29
JP6793621B2 (ja) 2020-12-02
CA2745470A1 (en) 2010-06-10
PT2364156T (pt) 2018-04-24
BRPI0917075A2 (pt) 2016-08-02
PE20150889A1 (es) 2015-06-07
ES2667773T3 (es) 2018-05-14
WO2010064204A3 (en) 2010-12-02
MX2011005815A (es) 2011-09-30
CO6390115A2 (es) 2012-02-29
JP2018024700A (ja) 2018-02-15
CL2011001309A1 (es) 2012-03-16
CR20110377A (es) 2011-10-20
CA2745470C (en) 2018-09-25
EP2364156B1 (en) 2018-01-31
CN102281884A (zh) 2011-12-14
PE20110942A1 (es) 2011-12-30
JP2016000045A (ja) 2016-01-07
AU2009323734B2 (en) 2016-06-30
US20120093871A1 (en) 2012-04-19
NZ593106A (en) 2013-05-31
US9463229B2 (en) 2016-10-11
AR074458A1 (es) 2011-01-19
MX351579B (es) 2017-10-20
WO2010064204A2 (en) 2010-06-10
ECSP11011171A (es) 2011-09-30
AU2009323734A1 (en) 2010-06-10
CN102281884B (zh) 2015-09-30
BRPI0917075B1 (pt) 2019-11-12
JP2012510286A (ja) 2012-05-10
EP2364156A2 (en) 2011-09-14

Similar Documents

Publication Publication Date Title
CL2008003406A1 (es) Compuestos derivados de quinolina; composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vih.
CL2009000820A1 (es) Conjunto de artículos absorbentes desechables específicos del género, que comprende un artículo absorbente de uso masculino y otro de uso femenino formados por un chasis y un par de alas de contención, en las los artículos absorbventes se diferencian porque sus alas de contención difieren en al amenos una caracteristica estructural.
ECSP12011685A (es) Inmunoconjugados dirigidos
ES2572160T3 (es) Una nueva preparación farmacéutica para preeclampsia
AR052165A1 (es) Tratamiento de hepatitis c en la poblacion asiatica
CR11619A (es) Articulo impreso para desplegar imagenes que tienen definicion y profundidad mejorada
NO20081067L (no) Behandling med dihydropyndinkalsiumkanalblokkere og omega 3-fettsyrer, og et kombinasjonsprodukt derav
CA119341S (en) Goggle
GB2556203A (en) Near-eye display with stacked lightguides
MX2012008908A (es) Pelicula que se puede rotular con laser resistente al calor.
UY30042A1 (es) Nuevos derivados de alquilfosfolípidos con citotoxicidad reducida y usos de los mismos.
BRPI0909566A2 (pt) Linhagem de h. Polymorpha recombinante, processo de elaboração de etanol que compreende o cultivo da linhagem de h. Polymorpha recombinante e ácido nucleico recombinante
CL2009001195A1 (es) Adyuvante inmune que comprende un inhibidor de iap capaz de modular la actividad inmune; composicion farmaceutica y vacuna que lo comprenden; metodo para mejorar una respuesta inmune de un individuo; metodo para tratar un cancer en un individuo; metodo para tratar infeccion; metodo para tratar trastornos autoinmune.
EP2518150A3 (en) 5'Triphosphate oligonucleotide with blunt end and uses thereof
CO6710901A2 (es) Método de vitrificación de superficie con nitrógeno líquido
CL2018002834A1 (es) Protozoo modificado que expresa al menos dos proteínas variables de superficie (vsp), vacuna que lo comprende, procedimientos, usos y métodos (divisional solicitud 201101309)
CL2018002430A1 (es) Proteínas de fusión de enzimas lisosomales terapéuticas dirigidas, formulaciones asociadas y usos de las mismas
USD643872S1 (en) Font having interchangeable indicia
CL2010000831S1 (es) Chupete con porcion central prismatica dispuesta vertival de contorno trapecial invertido y liso, de vertices y lados oblicuos convexos con tramo central concavo en ambas bases, de superficie frontal convexa con protuberancia central transversal inicialmente tronco conica de base que se prolonga en una porcion prismatica de base semicircular lisa. (divisional sol. 2882-2008)
EA201100902A1 (ru) Новый способ получения рнк-вируса
AR087941A1 (es) Recipiente de vidrio con decoracion de pared sub-superficial y metodo de fabricacion
CL2018002042A1 (es) Metodos para la produccion de virus.
CL2011001079A1 (es) Kit de formulaciones farmaceuticas que comprende cuatro composiciones: una de oxigeno molecular, un complejo vitaminico, otro complejo mineral y una de levadura; uso en el tratamiento de pacientes con vih sida.
CL2008001295A1 (es) Metodo para la produccion de un virus que comprende proporcionar una celula huesped que ha sido infectada por el virus, cultivar la celula a dos diferentes temperaturas y recolectar el virus obtenido.
Cuk Animal imagery in contemporary Mexican theatre (German List Arzubide, Maruxa Vilalta, Emilio Carballido, Elena Garro, Martha Cerda)